Skip to NavigationSkip to content

Pharmafile - Sales and Marketing News

Fujifilm is now expected to forge ahead in securing regulatory approval in Japan and around the world. The company said it aims to submit a...
In the first study, the combo was found to generate an objective response rate of 21.4% in the treatment of unresectable or advanced melanoma which...
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance...
Acella Pharmaceuticals is recalling two types of its thyroid medication as the drugs may be too weak to properly treat those who take them.
Dr Susanne Schaffert, President of Novartis Oncology said: “These data demonstrating survival benefit give the 40% of HR+/HER2- advanced breast...
The Centers for Disease Control and Prevention has identified nearly 11,000 people who were potentially exposed to coronavirus while flying.
With this latest recommendation, the drug will now also be available for the treatment of advanced squamous or non-squamous NSCLC as a follow-up to...
The deal sees MSD gain access to Seattle Genetics’ LIV-1 inhibitor iadiratuzumab vedotin and tyrosine kinase inhibitor Tuksya.
Following investigation from independent committees and international regulators of generated safety data, the trial programme has now received the...
The primary focus of the deal for Gilead is Immunomedics’ Trop-2 directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy), which it...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches